{
    "id": 28101,
    "fullName": "ERBB3 D297Y",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ERBB3 (HER3) D297Y lies within the extracellular domain of the Erbb3 (Her3) protein (UniProt.org). The functional effect of D297Y is conflicting as it demonstrates increased cell proliferation, but not elevated downstream signaling in ER-positive breast cancer cells; however, leads to increased cell proliferation and downstream signaling in Erbb2 (Her2)-overexpressing cells relative to wild-type (PMID: 29963236), and in another study results in similar cell proliferation and viability levels as wild-type Erbb3 (Her3) (PMID: 29533785).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 11238,
                    "pubMedId": 29533785,
                    "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                },
                {
                    "id": 11673,
                    "pubMedId": 29963236,
                    "title": "Activating HER3 mutations in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29963236"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2065,
        "geneSymbol": "ERBB3",
        "terms": [
            "ERBB3",
            "c-erbB-3",
            "c-erbB3",
            "ErbB-3",
            "erbB3-S",
            "FERLK",
            "HER3",
            "LCCS2",
            "MDA-BF-1",
            "p180-ErbB3",
            "p45-sErbB3",
            "p85-sErbB3"
        ]
    },
    "variant": "D297Y",
    "createDate": "05/02/2018",
    "updateDate": "09/28/2019",
    "referenceTranscriptCoordinates": {
        "id": 123460,
        "transcript": "NM_001982",
        "gDna": "chr12:g.56088557G>T",
        "cDna": "c.889G>T",
        "protein": "p.D297Y",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 15658,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Nerlynx (neratinib) resulted in reduced colony formation of ERBB2 (HER2)-overexpressing breast cancer cells expressing ERBB3 (HER3) D297Y in culture relative to control treatment, however, at a much greater concentration than the minimal concentration required for ERBB2 (HER2) activating mutations (PMID: 29963236).",
            "molecularProfile": {
                "id": 31127,
                "profileName": "ERBB2 over exp ERBB3 D297Y"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11673,
                    "pubMedId": 29963236,
                    "title": "Activating HER3 mutations in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29963236"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15638,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Herceptin (trastuzumab) resulted in decreased colony formation in ERBB2 (HER2)-overexpressing breast cancer cells expressing ERBB3 (HER3) D297Y in culture (PMID: 29963236).",
            "molecularProfile": {
                "id": 31127,
                "profileName": "ERBB2 over exp ERBB3 D297Y"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11673,
                    "pubMedId": 29963236,
                    "title": "Activating HER3 mutations in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29963236"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15639,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination treatment of Perjeta (pertuzumab) and Herceptin (trastuzumab) resulted in decreased colony formation in ERBB2 (HER2)-overexpressing breast cancer cells expressing ERBB3 (HER3) D297Y in culture (PMID: 29963236).",
            "molecularProfile": {
                "id": 31127,
                "profileName": "ERBB2 over exp ERBB3 D297Y"
            },
            "therapy": {
                "id": 1389,
                "therapyName": "Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11673,
                    "pubMedId": 29963236,
                    "title": "Activating HER3 mutations in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29963236"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15637,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Perjeta (pertuzumab) resulted in decreased colony formation in ERBB2 (HER2)-overexpressing breast cancer cells expressing ERBB3 (HER3) D297Y in culture (PMID: 29963236).",
            "molecularProfile": {
                "id": 31127,
                "profileName": "ERBB2 over exp ERBB3 D297Y"
            },
            "therapy": {
                "id": 856,
                "therapyName": "Pertuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11673,
                    "pubMedId": 29963236,
                    "title": "Activating HER3 mutations in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29963236"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15653,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Tykerb (lapatinib) did not lead to reduced proliferation of ERBB2 (HER2)-overexpressing breast cancer cells expressing ERBB3 (HER3) D297Y in culture relative to control treatment (PMID: 29963236).",
            "molecularProfile": {
                "id": 31127,
                "profileName": "ERBB2 over exp ERBB3 D297Y"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11673,
                    "pubMedId": 29963236,
                    "title": "Activating HER3 mutations in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29963236"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 29670,
            "profileName": "ERBB3 D297Y",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31127,
            "profileName": "ERBB2 over exp ERBB3 D297Y",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 123460,
            "transcript": "NM_001982",
            "gDna": "chr12:g.56088557G>T",
            "cDna": "c.889G>T",
            "protein": "p.D297Y",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}